Search details
1.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(4): 319-332, 2023 01 26.
Article
in English
| MEDLINE | ID: mdl-36511784
2.
Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.
Blood
; 2024 Apr 18.
Article
in English
| MEDLINE | ID: mdl-38635762
3.
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.
Blood
; 141(21): 2576-2586, 2023 05 25.
Article
in English
| MEDLINE | ID: mdl-36913694
4.
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Blood
; 139(9): 1330-1339, 2022 03 03.
Article
in English
| MEDLINE | ID: mdl-34570879
5.
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
Blood
; 139(26): 3722-3731, 2022 06 30.
Article
in English
| MEDLINE | ID: mdl-35439295
6.
Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies.
Haematologica
; 109(3): 835-845, 2024 Mar 01.
Article
in English
| MEDLINE | ID: mdl-37706363
7.
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Haematologica
; 2024 Jan 25.
Article
in English
| MEDLINE | ID: mdl-38268449
8.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol
; 20(12): 717-726, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38088119
9.
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Lancet Oncol
; 24(7): 811-822, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37414012
10.
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
Br J Haematol
; 200(1): 54-63, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36120837
11.
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Blood
; 137(3): 323-335, 2021 01 21.
Article
in English
| MEDLINE | ID: mdl-32967009
12.
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
Haematologica
; 108(1): 98-109, 2023 01 01.
Article
in English
| MEDLINE | ID: mdl-35833303
13.
CAR T-cell therapy for CLL: a new addition to our treatment toolbox?
Clin Adv Hematol Oncol
; 21(3): 134-141, 2023 Mar.
Article
in English
| MEDLINE | ID: mdl-36867557
14.
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
JAMA
; 329(11): 918-932, 2023 03 21.
Article
in English
| MEDLINE | ID: mdl-36943212
15.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(8): 1031-1043, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35810754
16.
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.
J Cell Mol Med
; 26(24): 5976-5983, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36453136
17.
Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.
Br J Haematol
; 197(2): 212-222, 2022 04.
Article
in English
| MEDLINE | ID: mdl-35106754
18.
The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
Br J Haematol
; 197(3): 306-309, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35149986
19.
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
Blood
; 135(19): 1650-1660, 2020 05 07.
Article
in English
| MEDLINE | ID: mdl-32076701
20.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Blood
; 136(10): 1134-1143, 2020 09 03.
Article
in English
| MEDLINE | ID: mdl-32688395